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Abstract 
Allogeneic hematopoietic stem cell transplantation is an emerging treatment option for solid tumors 
because of its capacity to elicit immune graft-versus-tumor effects. However, these are often limited and 
associated with GvHD. Adoptive recipient leukocyte infusion (RLI) was shown to enhance anti-tumor 
responses of allogeneic bone marrow transplantation in murine neuroblastoma (Neuro2A)-bearing 
chimeras. In contrast to the clinically used donor leukocyte infusion, the RLI anti-tumor effect –elicited by 
host-versus-graft lymphohematopoietic reactivity– does not cause GvHD; however the tumor growth-
inhibitory effect is incomplete because overall survival is not prolonged. Here, we studied the anti-solid 
tumor mechanisms of RLI with the objective to improve its efficacy. Host-versus-graft reactivity following 
RLI was associated with a systemic cytokine storm, lymph node DC activation and systemic expansion of 
host-derived IFN--expressing CD4+T cells and IFN--and granzyme B-expressing CD8+T cells, which acquired 
killing activity against Neuro2A and third-party tumor cells. The tumor showed up-regulation of MHC class I 
and a transient accumulation of IFN--and granzyme B-expressing CD8+T cells: the intra-tumor decline in 
cytotoxic CD8+T cells coincided with a systemic –and to a lesser extent intra-tumoral– expansion of MDSC. 
In vivo MDSC depletion with 5-FU significantly improved the local tumor growth-inhibitory effect of RLI as 
well as overall survival. In conclusion, the RLI-induced alloreactivity gives rise to a host-derived cytotoxic T 
cell anti-neuroblastoma response, but also drives an expansion of host-type MDSC that counteracts the 
anti-tumor effect. This finding identifies MDSC as a novel target to increase the effectiveness of RLI, and 
possibly other cancer immunotherapies.  
 
Keywords 
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Précis 
This work identifies MDSC as a key intervention target to improve the efficacy of RLI, and points to the 
need for combination therapies to counteract immune regulatory pathways that may limit the 
effectiveness of cancer immunotherapies. 
 
Abbreviations 
AlloBMT  Allogeneic bone marrow transplantation 
AlloHSCT  Allogeneic hematopoietic stem cell transplantation  
APC     Allophycocyanin 
CBA   Cytometric bead array 
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CCL2   Chemokine (C-C motif) ligand 2 
DLI   Donor leukocyte infusion 
FasL   Fas ligand 
GvHD  Graft-versus-host disease 
GvT   Graft-versus-tumor 
iNKT   Invariant natural killer T cells 
M-/G-MDSC  Monocytic/Granulocytic myeloid-derived suppressor cells 
MHC-I   MHC class I 
MHC-II   MHC class II 
NO  Nitric oxide 
NOD/SCID Nonobese diabetic/severe combined immunodeficiency 
RLI   Recipient leukocyte infusion 
Th1   T helper 1 cells 
Treg    T regulatory cells 
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Introduction 
Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been the cornerstone in the treatment of 
hematological malignancies for decades [1], and is now also emerging as a treatment option for solid 
tumors, such as renal cell carcinoma, breast cancer [2], and neuroblastoma (clinicaltrials.gov) [3,4]. The 
therapeutic effect of alloHSCT has been attributed to donor T cells attacking the tumor (graft-versus-tumor 
(GvT) effect). However, donor T cells may also target healthy recipient tissues, resulting in GvHD, causing 
important morbidity and mortality. Removal of T cells from the donor graft obviates GvHD but results in 
higher relapse rates [5]. This has led to the use of post-transplant donor leukocyte infusion (DLI) to re-
enforce anti-tumor responses. DLI can reinduce remission in patients with post-transplant relapse: a strong 
lymphohematopoietic donor-anti-host response occurs with rapid conversion of mixed towards full donor 
chimerism, which is accompanied by effective GvT effects. However, the risk for GvHD, albeit lower than 
immediately after transplantation, is still significant [6] which stimulates research into safer alternatives to 
enhance anti-tumor effects after alloHSCT.  
Adoptive cell therapy with non-tolerant recipient-type –rather than donor-type– leukocytes (recipient 
leukocyte infusion, RLI) has recently been explored experimentally, inspired by the observation that some 
advanced hematological cancer patients who showed spontaneous loss of the donor graft still experienced 
remission [7]. Studies in murine leukemia models performed by our group and others have shown that RLI 
can indeed mount anti-leukemia effects when given after allogeneic BMT (alloBMT). RLI into tolerant mixed 
BM chimeras provokes a lymphohematopoietic host-versus-graft reaction resulting in full rejection of the 
donor graft while producing anti-tumor responses and –importantly– leaving host tissues intact. The 
observed anti-leukemia mechanisms are thought to be elicited by the alloreactivity and presumed to 
involve activated host APC that cross-present allogeneic and tumor Ags and in turn activate host CD4+ and 
CD8+ T cells as well as invariant natural killer T (iNKT) cells and NK cells, but also direct reactivity of RLI-
derived non-tolerant IFN--producing CD8+ T cells against the host tumor [8–11].  
The potential of RLI to reinforce post-transplant anti-leukemia reactivity without provoking GvHD and the 
growing interest in alloHSCT for therapy-resistant solid tumors, led us to explore RLI in a solid tumor mouse 
model, specifically neuroblastoma [12]. Neuroblastoma is the most common extra-cranial solid tumor in 
childhood. The majority of patients is diagnosed with high-risk disease and faced with poor prognosis 
despite intensive therapy. Although the currently available treatment has improved the patients outcome 
over the last few years, high treatment-related toxicity and relapse rates still cause high mortality rates, 
urgently calling for further research into novel strategies [13,14]. Available clinical data show that alloHSCT 
is feasible to exploit graft-versus-neuroblastoma responses and improve the outcome, but disease 
recurrence remains the major cause of treatment failure [3,4].  
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We found in allogeneic BM transplanted mice carrying neuroblastoma that RLI delays local growth and 
metastasis of neuroblastoma [12], providing first evidence that RLI may effectively target a solid tumor. 
However, although local tumor growth is significantly reduced by RLI, the tumor-inhibitory effect is 
incomplete since overall survival is not prolonged. In the present study we aimed to gain a detailed insight 
into the dynamics and mechanisms of the anti-neuroblastoma response of RLI, with the objective to define 
a strategy to optimize the efficacy. 
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Materials and methods  
Mice 
Female A/J (H2Kk, 12-weeks-old) recipient mice and C57Bl/6 (H2Kb, 8-weeks-old) donor mice were obtained 
from Envigo (Venray, The Netherlands; Camebridgeshire, UK) and Janvier Labs (Saint Berthevin, France). 
Transplanted mice received water supplemented with enrofloxacine (Baytril 10% 2ml/l) as prophylaxis 
post-irradiation.  
 
Tumor cell lines 
The Neuro2A tumor cell line (ATCC, Rockville, MD, USA) is a cell line derived from a neuroblastoma tumor 
that spontaneously arose in A/J mice [15]. Experimental tumors are induced by s.c. inoculation of 1x106 
Neuro2A cells into the left flank.  
The P815 cell line (ATCC) is a mastocytoma-derived tumor cell line used as target cell line for in vitro 
cytotoxicity assays.  
 
Allogeneic BMT  
Recipient A/J mice received 9 Gray total body irradiation prior to transplantation (day -1). On day 0 
reconstitution with allogeneic hematopoietic stem cells was performed as described previously [16]. BM 
cells were harvested from the tibias and femurs of donor C57Bl/6 mice. T cells were depleted from the 
donor marrow using cytotoxic complement-fixing anti-Thy1.2 and low-toxic rabbit complement (Serotec, 
Oxford, UK). Finally, 5x106 T cell-depleted allogeneic BM cells were injected i.v. into a tail vein of A/J 
recipient mice.  
 
Recipient leukocyte infusion and MDSC depletion 
Spleens were harvested from naive A/J mice and single cell suspensions were prepared using a GentleMACS 
Dissociator (Myltenyi Biotec, Leiden, The Netherlands). Cells were filtered and rinsed twice with RPMI1640. 
50x106 splenocytes/250l RPMI1640 were injected i.v. into a tail vein of A/J chimeras at day 21 post-
alloBMT. 
For in vivo MDSC depletion, mice were injected i.p. with 5-FU at 50mg/kg body weight on day 30 post-
alloBMT. 
 
In vitro CD8 T lymphocyte cytotoxicity assay 
To evaluate in vitro cytotoxicity of effector CD8+ T cells from chimeric mice, standard 51Cr-release assays 
were performed. In brief, CD8+ T cells were isolated using MACS, according to the manufactures’ 
instructions. Target tumor cells were labeled with 51Cr (MP Biomedicals, Irvine, CA; 100 Ci/test), followed 
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by a 4 hour-incubation at 37°C with MACS-purified CD8+ T cells. After incubation, supernatant was collected 
and 51Cr release was measured using a Topcount gamma counter (Packard Instrument Company, Meriden, 
USA).  
 
Trypan blue exclusion assay and proliferation assay 
To study the direct tumor killing effect of IFN-, Neuro2A cells were co-cultured with recombinant murine 
IFN- (PeproTech Inc, Rocky Hill, USA; 50-30000 pg/ml) for 6, 12, 24 or 48 hours. After incubation, Neuro2A 
cells were either harvested to add Trypan blue and count the number of dead cells using a Bürker chamber, 
or 3H-thymidine (MP Biomedicals, Irvine, CA; 1Ci/test) was added to count 3H-thymidine uptake after 
incubation using a Microbeta TriLux counter (PerkinElmer, Shelton, USA).  
 
Suppressor assay 
To determine the ability of MDSC to inhibit T cell proliferation, splenic CD3-Gr1+MDSC were purified from 
RLI chimeras at day 35 using MACS, and were subsequently added in a 1:1 ratio to MACS-purified CD3+ T 
cells from spleens of RLI chimeras at day 35 (responders) mixed with mitomycin C (Kyowa Hakko, Tokyo, 
Japan)-inactivated C57Bl/6 splenocytes (stimulators) or medium as control. On day 4 of incubation, 3H-
thymidine was added and cells were harvested after 18h of culture. 3H-thymidine uptake was measured 
using a Microbeta TriLux counter. 
 
FACS 
FACS was performed using a LSR Fortessa (BD, Mountain View, CA, USA). PBL was collected by retro-orbital 
puncture and red blood cells were lysed using NH4Cl. Spleen and LN were isolated and single cell 
suspensions were prepared. Tumors were excised, incubated in a mixture of Collagenase D (2mg/ml) and 
DNase (20µg/ml) (Sigma-Aldrich, Overijse, Belgium) in RPMI1640 containing 10% FCS, and leukocytes were 
separated by Percoll density gradient. Cells were stained with fluorochrome-conjugated mAb against CD45 
(V500), CD3 (PerCP-Cy5.5), H2Kb (FITC), CD4 (eF450), CD8 (APCeF780), CD19 (APCeF780), NK1.1 
(APCeF780), CD11c (PerCPCy5.5), CD11b (eF450), Ly6C (PerCPCy5.5), Ly6G (APCeF780), IEk (PE), IAk (PE) 
(eBioscience, Vienna, Austria), H2Kk (PE), CD80 (BV605) CD86 (BV510) (BD) and NKp46 (APC) (Biolegend, 
San Diego, USA). For intracellular stainings, cells were restimulated for 4 hours with 100 ng/ml PMA, 1 
g/ml ionomycin and 0.7 g/ml monensin (Sigma-Aldrich) prior to surface staining. Cells were fixed, 
permeabilized and intracellularly stained with PE-conjugated anti-IFN-, anti-granzyme B or anti-Fas ligand 
(FasL) mAb (eBioscience). Intracellular FOXp3 was detected using the eBioscience Fixation & 
Permeabilization buffer set and allophycocyanin (APC)-conjugated anti-FOXp3 mAb (eBioscience). Data 
were analyzed with FlowJo software (Tree Star, Ashland, OR). 
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Cytometric bead array (CBA) assay 
Release of TNF-α, IFN-, IL-2, IL-6, IL-10, IL-12 and IL-17 was quantified by a CBA assay (BD) according to the 
manufacturer’s instructions. Samples were acquired using the LSR Fortessa and data were analyzed with 
FCAP Array software v3.0 (BD). 
 
Statistical analysis  
Statistical significance between 2 groups was determined by Mann-Whitney U test. Two-way ANOVA was 
performed to determine statistical significance between 2 groups on different time points. Log-rank test 
was used to determine statistical significance of survival curves. A P-value <0.05 was considered statistical 
significant. Statistics were performed using GraphPad Prism 6 Software. 
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Results 
RLI alloreactivity is associated with a systemic cytokine storm and host T cell expansion.  
As shown previously, infusion of recipient leukocytes (RLI) into mixed chimeras significantly delayed local 
neuroblastoma tumor growth (Fig. 1a) [12]. The anti-tumor effect coincided with strong host-anti-donor 
lymphohematopoietic alloreactivity as evident from a full rejection of donor T-, B-and NK-cell chimerism 
within 2 weeks after RLI (Fig. 1b). RLI-derived T cells but not NK cells were the mediators of alloreactivity: 
rejection still occurred when NK cell-depleted RLI was given, but donor chimerism remained unchanged 
after T cell-depleted RLI (Supplementary Figure 1).  
Lymphohematopoietic alloreactivity was associated with a marked expansion of host CD4+ T cells at day 35, 
and host CD8+ T cells at day 28 and 35 post-alloBMT, compared to control chimeras. Donor CD4+ and CD8+ T 
cells were almost absent in RLI chimeras, consistent with the allorejection post-RLI. In control chimeras, low 
numbers of donor T cells on day 28 increased towards day 35, likely due to further donor engraftment post-
alloBMT (Fig. 1c and d). B-and NK cell numbers were very low after RLI, since almost all B- and NK cells were 
donor-type at day 20 (Fig. 1b) and RLI fully rejects the donor B-and NK cell chimerism (Fig. 1e and f). As 
shown in Fig. 1g, the alloreactive response was also associated with an inflammatory cytokine storm: 
significantly elevated levels of IFN-, TNF-α, IL-6 and IL-10 were observed in serum of RLI chimeras as 
compared to control chimeras and naive animals, with levels peaking at day 26 post-alloBMT. Whereas IL-6 
and IL-10 levels were only transiently enhanced, serum levels of IFN- and TNF-α remained significantly 
elevated. Serum levels of IL-2, IL-12 and IL-17 were not increased after RLI (Supplementary Figure 2). 
 
RLI generates host CTL responses in spleen and LN.  
To study the effector T cell pathways of the anti-tumor effect, flow cytometry was performed on spleens 
from chimeras at day 28 and 35 post-alloBMT. Absolute numbers of host-derived IFN-+CD4+ T lymphocytes 
were significantly higher in RLI chimeras compared to controls, both at day 28 and 35 (Fig. 2a). A trend 
towards increased numbers of host granzyme B+CD4+ T cells was also observed in RLI chimeras at day 28 
that became significant by day 35 (Fig. 2b). The numbers of host IFN-+CD8+ T cells and granzyme B+CD8+ T 
cells were significantly higher in RLI chimeras than in controls at day 28 and 35 (Fig. 2c and d). Significantly 
enhanced numbers of host FasL+CD8+ T cells were also observed in RLI chimeras at day 35 compared to 
controls (Fig. 2e). A similar profile with increased expression of IFN-, granzyme B and FasL was observed in 
host CD4+ and CD8+ T lymphocytes in the LN of RLI chimeras (Supplementary Figure 3). Donor-type T helper 
1 (Th1) cells and CTL were not detectable in spleens of RLI chimeras, due to full rejection of donor 
chimerism. 
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Consistent with the observation of a primed Th1 and CTL response, we observed an expansion in the 
frequency of CD11c+ cells in the LN after RLI, together with a significant up-regulation in expression of 
CD80, CD86 and host MHC class II (MHC-II)  (Fig. 3a-d).  
Also consistent with the CTL expansion, CD8+ T lymphocytes purified from spleens of RLI chimeras at day 28 
or 35 showed significantly higher ex vivo cytotoxicity against Neuro2A than purified CD8+ T cells from 
control chimeras and naive A/J mice (Fig. 2f and g). CD8+ T cells from RLI chimeras also showed significantly 
higher killing activity against P815 than CD8+ T cells from controls (Fig. 2h).  
In conclusion, the RLI-induced lymphohematopoietic alloreactive response provides host CTL with killing 
activity against host-type neuroblastoma and a third-party tumor.  
 
Neuroblastoma up-regulate MHC class I after RLI. 
Cytokines may directly influence tumor immunogenicity by modulating expression of MHC class I (MHC-I) 
molecules. H2Kk expression was significantly higher on tumor cells of RLI chimeras than on those of control 
chimeras, both at day 28 and 35 post-alloBMT (Fig. 4a). As demonstrated in Fig. 4b, in vitro co-culture of 
Neuro2A cells with IFN- or TNF-α for 48 hours showed that IFN- but not TNF-α significantly up-regulated 
H2Kk on neuro2A cells, and this in a dose-dependent manner (Supplementary Figure 4). In vitro cultures of 
Neuro2A cells with increasing concentrations of IFN- resulted neither in increased numbers of dead 
Neuro2A cells, nor in decreased tumor proliferation (Supplementary Figure 5).  
We conclude that Neuro2A cells up-regulate MHC-I in response to the cytokine storm. This is presumed to 
be –at least in part– mediated by IFN- while it has no direct killing effect against neuroblastoma.  
 
RLI facilitates infiltration of host CTL into the tumor. 
The tumor growth-inhibiting effect of RLI would require effector cells to infiltrate into the solid tumor 
environment. Effector T cell-numbers were analyzed within tumors from chimeras at day 28 and 35 post-
alloBMT. Significantly higher numbers of host IFN-+CD4+ T cells were observed in tumors from RLI chimeras 
at day 28 compared to control chimeras. At day 35, the numbers had declined but were still significantly 
higher compared to controls. In tumors of both RLI and control chimeras, only low numbers of donor-type 
IFN-+ CD4+ T cells were present (Fig. 4c). Although host granzyme B+CD4+ T cells were shown to expand in 
spleens of RLI chimeras (Fig. 2b), this was not seen within the tumor (Fig. 4d). Significantly higher numbers 
of host IFN-+CD8+ T cells and granzyme B+CD8+ T cells were observed within tumors of RLI chimeras 
compared to controls, both at day 28 and 35, although the difference became smaller with time (Fig. 4e-f). 
The presence of IFN--producing CD8+ T cells was also confirmed by immunofluorescence stainings (Fig. 4g).  
In tumors of both RLI and control chimeras, donor-type IFN-+CD8+ and granzyme B+CD8+ T cells were very 
low, indicating that donor T cells contribute little to no anti-tumor reactivity (Fig. 4e and f). In conclusion, 
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the lymphohematopoietic response of RLI allows host Th1 cells and CTL to migrate into the solid tumor 
environment by day 28, but this effect seems transient as the absolute numbers have already strongly 
declined by day 35.  
 
RLI-mediated alloreactivity induces an expansion of granulocytic and monocytic MDSC.  
In contrast to the persisting effector T cell presence in the systemic compartment, within the tumor 
effector T cells seemed to decline by day 35. These opposing dynamics along with the observation that the 
tumor growth-inhibitory effect of RLI is incomplete, suggested that an immunoregulatory mechanism 
interferes with the intra-tumor effector pathway. We examined possible involvement of MDSC and T 
regulatory (Treg) cells, both of which have been reported as regulators of alloreactivity and anti-tumor 
reactivity [17–20]. MDSC can be induced by tumors as an immune escape mechanism [21], and are also 
known to be influenced in various contexts of immune stimulation and inflammation, such as auto-
immunity, transplantation and alloreactivity [19,20,22]. We determined absolute numbers of the two major 
subsets: monocytic MDSC (M-MDSC; CD11b+Ly6G-Ly6C+) and granulocytic MDSC (G-MDSC; 
CD11b+Ly6G+Ly6C-), which have both shown to be immunosuppressive [22]. Whereas on day 28 clear 
differences in numbers of splenic MDSC could not be seen, on day 35 a strong expansion of host M-MDSC 
and G-MDSC was observed in RLI chimeras relative to controls (Fig. 5a and b). These expanded MDSC were 
able to functionally suppress T cell proliferation in RLI chimeras, as evident from ex vivo suppression assays 
showing significant inhibition of T cell proliferation when MDSC were added (Supplementary Figure 6). 
Donor M-MDSC or G-MDSC were not detected in spleens of RLI chimeras, consistent with the rejection of 
donor myeloid cells post-RLI (Fig. 5a and b). In the tumors of RLI chimeras, a small but significant increase in 
numbers of host M-MDSC and G-MDSC was observed by day 35. Donor-type MDSC were detected in low 
numbers due to the allorejection, while in control chimeras such donor M-MDSC and G-MDSC were clearly 
present (Fig. 5c and d).  
No higher quantities of host and donor Treg cells were observed in RLI chimeras than in controls, both in 
spleen and tumor (Fig. 5e and f).  
Together, the RLI-induced alloreactivity is followed by a strong splenic expansion of host-type M-MDSC and 
G-MDSC with potent T cell proliferation suppressive activity, which –although to a lesser extent– also 
become visible in the tumor environment. 
 
MDSC depletion improves the anti-tumor effect of RLI. 
We postulated that the MDSC accumulation is responsible for limiting the migration (and/or further 
expansion) of effector T cells into the tumor, hence also the incomplete RLI-effect in limiting tumor growth 
and improving survival (Fig. 1a). MDSC were depleted in vivo in RLI chimeras by injecting 5-FU (50mg/kg) on 
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day 30 post-alloBMT (Fig. 6a). 5-FU is a chemotherapeutic agent that was shown to selectively deplete 
MDSC within 5 days when administered at a low-dose (50mg/kg) [23]. FACS on spleens from RLI chimeras 
at day 35 showed that both M-MDSC and G-MDSC were indeed depleted after 5-FU treatment 
(Supplementary Figure 7). Strikingly, although RLI treatment in chimeras could not improve the overall 
survival relative to control chimeras, treatment of RLI chimeras with 5-FU resulted in significantly stronger 
tumor growth reduction and significantly prolonged survival, compared to chimeras treated with RLI only 
(Fig. 6b and c). Importantly, 5-FU was not able to impair local tumor growth in Neuro2A-bearing nonobese 
diabetic/severe combined immunodeficiency (NOD/SCID) mice (Supplementary Figure 8), indicating that 5-
FU has no direct tumor killing effect. In conclusion, depletion of MDSC enhances the tumor growth-
inhibitory effect of RLI at the local level as well as survival, suggesting that the MDSC expansion is –at least 
in part– responsible for the incomplete biological effect of RLI.  
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Discussion 
In this study, we demonstrate that the lymphohematopoietic alloreactivity of RLI generates a host-derived 
cytotoxic T cell anti-neuroblastoma response, but also drives an expansion of host-type MDSC that 
counteracts the tumor growth-inhibitory effect of RLI. The MDSC expansion coincides with the decline of 
intra-tumor host-type effector T cells, presumably due to inhibition of migration of the systemically-
generated effector cells into the tumor. Within the tumor MDSC also start to accumulate –albeit with a 
small delay– where they may directly inhibit T cell effector functions. These findings identify MDSC as a 
new target to improve the effectiveness of RLI, and possibly other cancer immunotherapies.  
Expansion of host CD4+ and CD8+ T cells along with a cytokine storm and DC activation is observed in 
association with the RLI-induced alloreactivity. Analogous to the immune mechanisms proposed in RLI 
leukemia models [11,24], we postulate that the systemic alloresponse in tumor-bearing chimeras provides 
host T lymphocytes with cytotoxic potential against the solid neuroblastoma tumor. This is also evident 
from ex vivo CD8+ T cell cytotoxicity assays, in which T cells derived from RLI chimeras showed enhanced 
killing activity against Neuro2A and a third-party tumor cell line. The latter observation indicates that the 
killing activity of CTL is –at least in part– non-specific.  
Importantly, the systemic alloresponse and associated cytokine storm with DC activation seem to facilitate 
migration of the systemically-generated host effector T lymphocytes into the tumor, as evident from the 
intra-tumor accumulation of host-type Th1 cells and CTL. The finding of CTL within the tumor is in line with 
prior observations in murine leukemia models that pointed to IFN--producing CD8+ T cells and CD4+ T-cell 
help in the anti-leukemia effector response of RLI [8]. RLI carries the additional advantage of rendering the 
tumor more susceptible to the effector CTL, as neuroblastoma cells up-regulated MHC-I after RLI. In line 
with reports on human tumor cells [25], Neuro2A up-regulated MHC-I in in vitro IFN- stimulation assays, 
based on which we presume that the up-regulation of MHC-I on Neuro2A tumor cells in vivo is –at least in 
part– mediated by IFN-. IFN- is released systemically during the cytokine storm, which most likely induces 
the MHC-I up-regulation on the tumor cells; IFN- is also produced within the tumor microenvironment by 
RLI-induced effector T cells, which presumably regulates the prolonged MHC-I up-regulation. This is in 
accordance with other studies reporting an important role for IFN- in the tumor microenvironment in 
allowing tumor responsiveness through various mechanisms, such as regulating CTL trafficking and up-
regulating MHC-I [26,27].  
Whereas previous work in the neuroblastoma model showed the presence of cytotoxic NK cells within 
tumors of RLI chimeras [12], our more recent data revealed that absolute numbers of such NK cells are very 
low as a consequence of full rejection of donor NK cell chimerism and slow NK cell recovery from the host 
compartment. Although this indicates that -relative to CD8+ T cells- the role of NK cells in the baseline RLI-
effect is probably limited, our prior observation that adoptive host NK cell therapy in RLI chimeras 
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enhanced the anti-tumor effect [12] indicates that the potential of NK cells may be synergistic and may be 
exploited in combination  adoptive cell therapy.  
The opposing dynamics of a persisting systemic and a declining intra-tumor effector T cell population along 
with a progressive systemic expansion of MDSC, led us hypothesize that the accumulating MDSC play a 
causal role in the incomplete RLI-effect on tumor growth and survival. Indeed, MDSC depletion in RLI 
chimeras using 5-FU resulted in significantly stronger inhibition of local tumor growth as well as improved 
overall survival. Although widely used as chemotherapeutic agent for several cancers including breast and 
colorectal cancer [28], low-dose 5-FU was shown in murine models to selectively trigger apoptosis in MDSC; 
in vitro and in vivo assays showed that administration of such low dose depletes MDSC without killing 
tumor cells or altering levels of other immune cells [23]. Analogously, low-dose 5-FU in RLI chimeras 
resulted in elimination of MDSC and in NOD/SCID mice we established that 5-FU had no direct Neuro2A 
killing effect. 
MDSC accumulation occurs in a variety of conditions, first and foremost as immune-escape mechanism 
associated with tumor development [21,29]. Increased levels of MDSC-like cells have been detected in 
blood of neuroblastoma patients [30], however, in our neuroblastoma-bearing control chimeras this was 
not seen. MDSC expansion has also been documented in conditions of inflammation and auto-immunity in 
mouse models [22], and in association with alloHSCT and alloreactivity in mice and humans [20,31,32]. 
Because the MDSC expansion was seen exclusively in RLI chimeras and closely followed the donor 
chimerism rejection, we postulate that MDSC expand as a result of reactive host myelopoiesis -as observed 
in previous BMT models [18,19]- and the alloreactive inflammation. Specifically, given the known ability of 
IL-6 and IL1- to drive MDSC accumulation [33], and IFN- to enhance the suppressor activity of MDSC [34–
36], we postulate that the RLI-associated cytokine storm plays a critical role in driving MDSC expansion.  
Since the intra-tumor CTL accumulation and splenic MDSC expansion show opposite and sequential 
dynamics, we hypothesize that the MDSC limit the migration of systemically-generated CTL into the tumor. 
MDSC release reactive nitrogen species such as peroxynitrite that can modify chemokines involved in CTL 
recruitment. For example, it was reported in murine models that peroxynitrite induces nitration of 
chemokine (C-C motif) ligand 2 (CCL2), thereby blocking T cell infiltration into the tumor [22,37]. MDSC 
possess, in addition to their inhibiting effect on lymphocyte trafficking, various other immune-inhibitory 
mechanisms [38–41], such as stimulation of tumor angiogenesis, stimulation of metastasis, negative 
modulation of the tumor microenvironment by inducing expansion of Treg cells and skewing of 
macrophage differentiation towards a pro-tumoral M2 phenotype. These mechanisms are potentially also 
involved in limiting the RLI-effect, and this is the subject of ongoing investigations. In addition to the strong 
MDSC expansion in the spleen, a quantitatively small but significant expansion of M-MDSC and to a lesser 
extent G-MDSC is seen in the tumor towards day 35 post-alloBMT. This delay -relative to the systemic 
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expansion- suggests that splenic MDSC also migrate into the tumor where they may directly inhibit CTL 
function. Of note, in contrast to the complete elimination of donor hematopoietic cells within 2 weeks 
following RLI, donor G-MDSC persist in tumors of RLI chimeras at day 28 and –to a lesser extent– at day 35. 
We postulate that the RLI-mediated allorejection of this donor-type cell population is more difficult within 
the tumor tissue than in the hematopoietic compartment, especially since RLI concurrently seems to drive 
an expansion of MDSC within this time frame.  
MDSC can inhibit T cell functions via diverse mechanisms, including production of immunosuppressive 
cytokines (such as IL-10 and TGF-), up-regulation of arginase 1 that depletes L-arginine and L-cysteine 
which are essential for T cell proliferation and cytotoxic activity, and production of reactive oxygen species 
and NO causing T cell hyporesponsiveness [21,42]. Although we have not investigated later time points, this 
effect may be progressive beyond day 35, when the tumor seems to escape the immune control and grows 
exponentially.  
An expansion of cytotoxic CD4+ T cells was also observed in the systemic compartment but within the 
tumor the results were inconsistent between animals. The existence of cytotoxic CD4+ T cells has been 
increasingly recognized. In contrast to the well-known T helper function, recent findings indicate that CD4+ 
T cells can exert cytotoxic functions when CTL are insufficient [43]. Homma et al. showed in a murine 
hepatocellular carcinoma model that the anti-tumor activity of a DC vaccine therapy was abrogated when 
CD4+ T cells were depleted [44]. In a murine retrovirus-induced tumor model Akhmetzyanova et al. showed 
that tumor development coincided with granzyme B+CD4+ T cell expansion that induced complete tumor 
regression in the absence of Treg cells and CD8+ T cells [45]. Since in our model granzyme B+CD4+ T cells 
were clearly induced in tumors of some RLI chimeras but not in others, we hypothesize that MDSC may also 
variably influence the influx and involvement of cytotoxic CD4+ T cells in the RLI-effect. 
Whereas RLI offers the critical advantage over DLI of not causing GvHD, its anti-tumor effect in leukemia 
and neuroblastoma models is significantly weaker than that of DLI [11,12,24]. MDSC have been shown in 
other transplant models to influence the critical balance between GvT and GvHD [19], and strikingly our 
current data indicate that by interfering with MDSC the anti-tumor effect of RLI can be enhanced while 
GvHD is still prevented. Of note, attempts with combination therapy using RLI and checkpoint inhibitor 
anti-PD-1 –given at a dose of 100 g every 4 days– failed to augment the anti-tumor effects (unpublished 
observations). We speculate that this may be due to suppressive interference by the accumulating MDSC. 
Similarly, the MDSC may be responsible for the effect of adoptive NK cell therapy in previous studies, which 
was found to enhance the tumor growth-inhibitory effect of RLI but without improving overall survival [12]. 
Cancer immunotherapy is a rapidly evolving field, however, although durable responses have been 
obtained, for the majority of patients clinically relevant responses remain an elusive goal [46–48]. Several 
strategies under investigation use combined approaches triggering an effector response arm while 
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interfering with inhibitory pathways, giving promising results in both preclinical and clinical setting. 
Inhibition of IDO or Gr1+myeloid cells increased T cell-mediated tumor-inhibitory effects of anti-CTLA-4 in 
murine models of melanoma and mammary carcinoma, respectively [49,50]. Moreover, Treg cell-depletion 
in renal cell carcinoma patients was shown to improve T cell responses mediated by DC vaccines [51]. In 
accordance with the observation in advanced renal cell carcinoma patients showing improved immune 
responses when MDSC were reduced [52], and a recent report showing that MDSC inhibition improved the 
efficacy of CAR therapy in sarcoma-bearing mice [53], our current data identify the MDSC regulatory 
pathway as a key intervention target for combination immunotherapy with RLI to improve its efficacy, not 
only for neuroblastoma but probably also for leukemia. Given the highly variable triggers of MDSC 
expansion and their diverse suppressor mechanisms, the MDSC pathway could be important in other types 
of cancer and anti-cancer immunotherapies. 
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Figure legends 
 
Fig. 1 Evolution of local tumor growth and alloreactivity after recipient leukocyte infusion 
 a. 1x106 Neuro2A cells were inoculated s.c. in allogeneic chimeras on day 14 post-alloBMT, and chimeras 
received either recipient leukocyte infusion (RLI) on day 21 post-alloBMT (‘alloBMT+RLI’ ) or no adoptive 
cell therapy (‘alloBMT’ ). After tumors were established (usually around day 9 after tumor inoculation, i.e. 
day 23 post-alloBMT), tumor growth was measured twice weekly using a caliper and the volume (mm3) was 
calculated (width2 x length x 0.52). Results shown are from 2 identically designed experiments. b. Evolution 
of peripheral blood donor chimerism levels in total B cells (blue lines), NK cells (black lines) and T cells 
(green lines) in control chimeras (‘alloBMT’ , full lines) and chimeras treated with RLI on day 21 post-
alloBMT (‘alloBMT+RLI’ , dotted lines). Results shown are from 4 experiments. c-f. Absolute numbers of 
CD4+ T cells (c), CD8+ T cells (d) (‘alloBMT’ n=8-10; ‘alloBMT+RLI’ n=10-13), CD19+ cells (e) (‘alloBMT’ n=6-9; 
‘alloBMT+RLI’ n=6-10), and NKp46+ cells (f) (‘alloBMT’ n=5-7; ‘alloBMT+RLI’ n=7-8) within host and donor 
compartment of spleens of RLI compared to control chimeras at day 28 and 35 post-alloBMT. g. Evolution 
of TNF-α, IFN-, IL-6 and IL-10 levels in serum from RLI chimeras (‘alloBMT+RLI’ , n=4-16), compared to 
control chimeras (‘alloBMT’ , n=3-12) and naive A/J mice (n=4). Bars represent SEM. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
Fig. 2 Induction of T helper 1 cells and CTL in the spleen after recipient leukocyte infusion 
 a-e. Absolute numbers of IFN-+CD4+ T cells (a), granzyme B+CD4+ T cells (b), IFN-+CD8+ T cells (c), 
granzyme B+CD8+ T cells (d) (‘alloBMT’ n=9-13; ‘alloBMT+RLI’ n=12-15), and FasL+CD8+ T cells (e) (‘alloBMT’ 
n=6-9; ‘alloBMT+RLI’ n=6-11) within host and donor compartment of spleens of RLI compared to control 
chimeras at day 28 and 35 post-alloBMT. f-h. CD8+ T cell reactivity against Neuro2A and P815 ex vivo. 
Standard 51Cr-release assays were performed to test cytotoxic activity of MACS-purified CD8+ T cells derived 
from spleens of RLI chimeras (‘alloBMT+RLI’), control chimeras (‘alloBMT’) or naive A/J mice against 
Neuro2A or P815. f-g. Ex vivo cytotoxicity against Neuro2A of CD8+ T cells isolated from spleens of chimeras 
at day 28 post-alloBMT (f) or at day 35 post-alloBMT (g). h. Cytotoxic capacity against P815 of CD8+ T cells 
isolated from spleens of chimeras at day 35 post-alloBMT. Results shown represent specific lysis of tumor 
target cells at a 50:1 E:T ratio. Results shown are from 1-3 identically designed experiments. Bars represent 
SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Fig. 3 Expansion and activation of DC in the LN of RLI chimeras 
LN were isolated from RLI and control chimeras at day 28 post-alloBMT. a. Frequency of CD11c+ cells in RLI 
chimeras (‘alloBMT+RLI’ ) compared to controls (‘alloBMT’ ). b-d. MFI values (left) and representative 
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histograms (right) of the expression of CD80 (b), CD86 (c) and IEk and IAk (d) on CD11c+ cells in RLI chimeras 
(‘alloBMT+RLI’ , filled histogram) and control animals (‘alloBMT’ , open histogram). Results shown are 
from 3 identically designed experiments. Bars represent SEM. *p<0.05, **p<0.01, ****p<0.0001.  
 
Fig. 4 MHC class I expression is enhanced on Neuro2A cells by IFN-, and higher numbers of host Th1 and 
CTL are found within tumors of RLI chimeras 
 a. Expression of H2Kk on Neuro2A tumor cells in vivo, collected from RLI chimeras (‘alloBMT+RLI’ , n=5-6) 
and control animals (‘alloBMT’ , n=4-5) at day 28 and 35 post-alloBMT, determined by FACS. b. Expression 
of H2Kk on Neuro2A cells, measured by FACS 48 hours after in vitro treatment of Neuro2A cells with 
medium (, n=4), 500 pg/ml IFN- (, n=5), 100 pg/ml TNF-α (, n=5), or 500 pg/ml IFN- plus 100 pg/ml 
TNF-α (, n=5), i.e. similar concentrations as the in vivo serum levels found after RLI treatment. c-f. Tumor 
tissues of RLI chimeras (‘alloBMT+RLI’) and controls (‘alloBMT’) were collected at day 28 and 35 post-
alloBMT to examine T cell infiltration into the tumor and cytotoxic profiles of intra-tumor T cells. Absolute 
numbers of IFN-+CD4+ T cells (‘alloBMT’ n=8-14; ‘alloBMT+RLI’ n=10-16) (c), granzyme B+CD4+ T cells 
(‘alloBMT’ n=8-10; ‘alloBMT+RLI’ n=9-11) (d), IFN-+CD8+ T cells (‘alloBMT’ n=8-14; ‘alloBMT+RLI’ n=10-16) 
(e), and granzyme B+CD8+ T cells (‘alloBMT’ n=8-10; ‘alloBMT+RLI’ n=9-11) (f) at day 28 and 35 post-alloBMT 
within host and donor compartment of the tumor, normalized to 100 mm3 tumor volume. Bars represent 
SEM. *p<0.05, **p<0.01, ****p<0.0001. g. IFN- (red) and CD8 (green) immunofluorescence stainings on 
tumor tissue sections of RLI chimeras (‘alloBMT+RLI’) and control chimeras (‘alloBMT’) at day 28 (upper 
panel) and 35 (lower panel) post-alloBMT. Scale bar, 50 m.  
 
Fig. 5 Expansion of host MDSC but not Treg cells in spleen and tumor of RLI chimeras 
a-b. Absolute numbers of monocytic MDSC (M-MDSC; CD11b+Ly6G-Ly6C+) (a) and granulocytic MDSC (G-
MDSC; CD11b+Ly6G+Ly6C-) (b) within host and donor compartment of spleens of RLI (‘alloBMT+RLI’ n=11-
17) and control chimeras (‘alloBMT’ n=12-16) at day 28 and 35 post-alloBMT. c-d. Absolute numbers of M-
MDSC (c) and G-MDSC (d) within host and donor compartment of tumors of RLI (‘alloBMT+RLI’ n=10-11) 
and control chimeras (‘alloBMT’ n=7-10) at day 28 and 35, normalized to 100 mm3 tumor volume. e. 
Absolute numbers of regulatory T (Treg) cells (CD4+FOXp3+ cells) in host and donor compartment of spleens 
of RLI (‘alloBMT+RLI’ n=6-16) and control chimeras (‘alloBMT’ n=5-16), at day 28 and 35 post-alloBMT. f. 
Absolute numbers of Treg cells in host and donor compartment of tumors of RLI chimeras (‘alloBMT+RLI’ 
n=10-11) compared to controls (‘alloBMT’ n=9-10) at day 28 and 35, normalized to 100 mm3 tumor volume. 
Bars represent SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Fig. 6 Biological effects of recipient leukocyte infusion combined with 5-FU to deplete MDSC 
 a. Recipient A/J mice received 9 Gy TBI followed by 5x106 TCD alloBMC at day 0, and were inoculated s.c. 
with 1x106 Neuro2A cells on day 14 post-alloBMT. Allogeneic chimeras received 50x106 A/J splenocytes 
(RLI) on day 21 post-alloBMT and were injected i.p. with 50 mg/kg 5-FU or saline on day 30 post-alloBMT. 
b-c. Evolution of tumor volume (b) and survival (c) of Neuro2A-bearing allogeneic bone marrow chimeras 
given no adoptive cell therapy (‘alloBMT’ ), or RLI with either 50 mg/kg 5-FU (‘alloBMT+RLI+5-FU’ ) or 
saline (‘alloBMT+RLI’ ). Results shown are from 2 identically designed experiments. Bars represent SEM. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Gy: Gray; TBI: Total body irradiation; TCD: T cell-depleted; 
alloBMC: allogeneic bone marrow cells. 
 
 
Supplementary Fig. 1 Alloreactivity after NK cell- or T cell-depleted recipient leukocyte infusion 
Evolution of peripheral blood donor T cell chimerism at selected time points after transplantation, in 
chimeras treated with RLI (‘alloBMT+RLI’ , black dotted line), RLI from which NK cells were removed by 
MACS (‘alloBMT+RLI w/o NK cells’ , blue line), T cell-depleted RLI (‘alloBMT+RLI w/o T cells’ , red line) or 
no RLI (‘alloBMT’ , black full line). Bars represent SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.    
 
Supplementary Fig. 2 Recipient leukocyte infusion is not associated with production of IL-2, IL-12 or IL-17  
Evolution of IL-2, IL-12 and IL-17 levels in serum from RLI chimeras (‘alloBMT+RLI’ , n=4-17), compared 
with control chimeras (‘alloBMT’ , n=3-12) and naive A/J mice (n=4). Bars represent SEM.  
 
Supplementary Fig. 3 Recipient leukocyte infusion increases expression of cytotoxic markers on host T 
cells in the LN 
 a-e. Cytotoxic profile of host CD4+ and CD8+ T cells in the LN of RLI (‘alloBMT+RLI’) and control chimeras 
(‘alloBMT’), at day 28 and 35 post-alloBMT. IFN- expression on host CD4+ T cells (‘alloBMT’ n=9-10; 
‘alloBMT+RLI’ n=11-12) (a), granzyme B production by host CD4+ T cells (‘alloBMT’ n=11-16; ‘alloBMT+RLI’ 
n=12-19) (b), IFN- on host CD8+ T cells (‘alloBMT’ n=10-12; ‘alloBMT+RLI’ n=13-16) (c), granzyme B 
expression on host CD8+ T lymphocytes (‘alloBMT’ n=11-16; ‘alloBMT+RLI’ n=12-19) (d) and FasL expression 
on host CD8+ T lymphocytes (‘alloBMT’ n=6-9; ‘alloBMT+RLI’ n=6-11) (e). Bars represent SEM. *p<0.05, 
**p<0.01, ****p<0.0001.  
 
Supplementary Fig. 4 IFN- treatment enhances H2Kk expression on Neuro2A cells in vitro in a dose-
dependent manner 
Neuro2A cells were co-cultured in vitro for 48 hours with increasing concentrations of IFN- (0-300000 
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pg/ml), followed by flow cytometric analysis to determine the expression of H2Kk on Neuro2A cells (MFI 
values are shown). Result shown is from 1 experiment. Bars represent SEM. 
 
Supplementary Fig. 5 IFN- has no direct killing effect on Neuro2A cells in vitro  
a. Neuro2A cells were co-cultured with different concentrations of IFN- (0-300000 pg/ml) for 6, 12, 24 or 
48 hours, and cell viability was assessed by a Trypan blue exclusion assay. Result shown is from 1 
experiment (n=4 per time point). b. Tumor cell proliferation was measured 24 and 48 hours after treatment 
of Neuro2A cells with increasing concentrations of IFN- (0-300000 pg/ml). Result shown is from 1 
experiment (n=4 per time point). Bars represent SEM.  
 
Supplementary Fig. 6 RLI-induced MDSC suppress T cell proliferation ex vivo 
MACS-purified CD3+ T cells from day 35 spleens of RLI chimeras (n=4) were stimulated with mitomycin C-
inactivated C57Bl/6 splenocytes (‘C57Bl/6’) or medium (control for proliferation). MACS-purified CD3-Gr1+ 
MDSC from day 35 spleens of the same RLI chimeras were added in a 1:1 MDSC:T cell ratio. Day 4 after 
culture, 3H-thymidine was added and T cell proliferation was assessed after 18h by measuring 3H-thymidine 
incorporation. Results shown are from 1 experiment. Bars represent SEM. *p<0.05. 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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